Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE expands Biosense Webster deal for ultrasound tech:

This article was originally published in Clinica

Executive Summary

GE Healthcare and Biosense Webster have extended a long-standing strategic partnership, with the aim of developing real-time ultrasound imaging technology for use in electrophysiology procedures. The partnership, of which financials details were not revealed, will see GE combine its ultrasound imaging capabilities with EP catheter technology belonging to Diamond Bar, California-based Biosense Webster. GE claims the two companies are to co-develop imaging solutions specifically for intracardiac therapies. The companies had previously built an alliance in order to integrate GE's CardioLab IT system for electrophysiology recording with Biosense Webster's Carto mapping system.

You may also be interested in...

P&G's $8M Benzene Settlement Preliminarily Approved By Ohio Federal Court

The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.

Food For Thought On US FDA Reforms

An independent review of the US FDA’s food regulatory programs could renew a debate over splitting FDA into two agencies. That could be a distraction for the agency in the coming year – but it could also help keep the medical product review groups out of the political hot seat.

FDA’s Win-Win: More Comprehensive IND Safety Reports With Minimal Effort Due To Harmonization

New proposed rule calls for replacing US FDA’s current annual reporting requirements for INDs with a safety update report that is consistent the format and content of the development safety update report (DSUR) supported by the International Council of Harmonisiation.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts